Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26690341 | 0.80 | — | — | |
| SCHEMBL1698052 | 0.79 | KMT2A (0.41) | L3MBTL1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL7067117 | 0.78 | — | — | |
| SCHEMBL17653501 | 0.77 | L3MBTL1 (0.35) | L3MBTL1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL8652771 | 0.76 | L3MBTL1 (0.37) | L3MBTL1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL17106178 | 0.76 | L3MBTL1 (0.41) | L3MBTL1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL17111461 | 0.72 | L3MBTL1 (0.38) | L3MBTL1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL6083788 | 0.72 | MEN1 (0.38) | L3MBTL1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL7767599 | 0.71 | L3MBTL1 (0.38) | L3MBTL1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL8255176 | 0.70 | L3MBTL1 (0.37) | L3MBTL1MEN1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4167934-A1 | FRAGRANCE MIXTURES CONTAINING 1-(4,4-DIMETHYLCYCLOHEXEN-1-YL) ETHANON | Symrise AG (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-11376198-B2 | Powder containing crystals comprising ingredients enclosed therein | SYMRISE AG (DE) | 2022-07-05 | — | — | US | disclosed |
| WO-2021254628-A1 | FRAGRANCE MIXTURES CONTAINING 1-(4,4-DIMETHYLCYCLOHEXEN-1-YL) ETHANON | SYMRISE AG (DE) | 2021-12-23 | — | — | WO | disclosed |
| US-11028034-B2 | Method for producing rotundone-containing mixtures | SYMRISE AG (DE) | 2021-06-08 | — | — | US | disclosed |
| US-20200247740-A1 | METHOD FOR PRODUCING ROTUNDONE-CONTAINING MIXTURES | SYMRISE AG (DE) | 2020-08-06 | — | — | US | disclosed |
| US-20200129385-A1 | POWDER CONTAINING CRYSTALS COMPRISING INGREDIENTS ENCLOSED THEREIN | SYMRISE AG (DE) | 2020-04-30 | — | — | US | disclosed |
| EP-1648526-A1 | CIS-3,3,5-TRIMETHYLCYCLOHEXYL ESTERS | Symrise GmbH & Co. KG (DE) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009492-A1 | CIS-3,3,5-TRIMETHYLCYCLOHEXYL ESTERS | SYMRISE GMBH & CO. KG (DE) | 2005-02-03 | — | — | WO | disclosed |
| EP-0542964-A1 | HYDROXY- OR OXO-SUBSTITUTED ALKYL CYCLOPENTENES. | GIVAUDAN ROURE INT (CH) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992022518-A1 | HYDROXY- OR OXO-SUBSTITUTED ALKYL CYCLOPENTENES | GIVAUDAN-ROURE (INTERNATIONAL) SA (CH) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028034-B2 | Method for producing rotundone-containing mixtures | TAS2R60, TAS2R16, TAS2R40 | L3MBTL1 4613/4885MEN1 332/4885ALDH1A1 1951/4885 |
| US-20200247740-A1 | METHOD FOR PRODUCING ROTUNDONE-CONTAINING MIXTURES | TAS2R60, TAS2R16, TAS2R40 | L3MBTL1 4613/4885MEN1 332/4885ALDH1A1 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.